Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 154-159

  Fung, Michael Fung Kee ^a   Reid, Amanda ^a   Faught, Wylam ^b   Le, Tien ^a,d   Chenier, C ^a   Verma, Shailendra ^a   Brydon, Elizabeth ^c   Fung, Karen Fung Kee ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Breast cancer; Endometrial cancer; Screening; Tamoxifen; Ultrasound

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; ENDOMETRIAL DISEASE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; METASTASIS; PATHOLOGY; POLYP; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY; UTERUS CANCER;

EID: 0141757455     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00441-4     Document Type: Article

References (27)

1. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer twenty-eight years later . J Clin Oncol. 13:1995;513-529.
2. Cuzick J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer. 36:2000;1298-1302.
3. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumour growth in athymic mouse. Cancer Res. 48:1988;812-815.
4. Huynh H., Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res. 54:1994;3115-3119.
5. Carlson R.W. Overview from a medical oncologist. Semin Oncol. 1:(suppl 1):1997;S151-157.
6. Suh-Burgmann E.J., Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med. 131:1999;127-135.
7. Exacoustos C., Zupi E., Cangi B., Chiaretti M., Arduini D., Romanini C. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen an ultrasound, color flow Doppler, hysteroscopic and histological study . Ultrasound Obstet Gynecol. 6:1995;425-442.
8. Kontostolis E., Stefanidis K., Navrozoglou I., Mouzakioti E., Paschopoulos M., Lolis D. The effects of tamoxifen on the endometrium, blood flow of the uterine arteries and serum lipoprotein (a) levels in postmenopausal women. Gynecol Endocrinol. 12:1998;185-189.
9. Dijkhuizen F.P., Brolmann H.A., Oddens B.J., Rourmen R.M., Coebergh J.W., Heintz A.P. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas. 25:1996;45-50.
10. Fleischer A.C., Kalemeris G.C., Machin J.E., Entman S.S., James A.E. Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultrasound Med. 5:1998;445-452.
11. Cohen I., Rosen D.J.D., Tepper R., et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 5:1993;275-280.
12. Love C.D.B., Muir B.B., Scimgeour J.B., Leonard R.C.F., Dillon P., Dixon J.M. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 17:1999;2050-2054.
13. Kedar R.P., Bourne T.H., Powles T.J., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 343:1994;1318-1321.
14. Achiron R., Lipitz S., Frenkel Y., Mashiach S. Endometrial blood flow response to estrogen replacement therapy and tamoxifen in asymptomatic, postmenopausal women a transvaginal Doppler study . Ultrasound Obstet Gynecol. 5:1995;411-414.
15. Strauss H.G., Wolters M., Methfessel G., Buchmann J., Koelbl H. Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the endometrium a prospective study . Acta Obstet Gynecol Scand. 79:2000;697-701.
16. Exacoustos C., Zupi E., Cangi B., Chiaretti M., Arduini D., Romanini C. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen an ultrasound, color flow Doppler, hysteroscopic and histological study . Ultrasound Obstet Gynecol. 6:1995;435-442.
17. Mourits M.J., Van der Zee A.G., Willemse P.H., Ten Hoor K.A., Hollema H., De Vries E.G. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol. 73:1999;21-26.
18. Giorda G., Crivellari D., Veronesi A., Perin T., Campagnutta E., Carbone A., Scarabelli C. Comparison of ultrasonography, hysteroscopy, and biopsy in the diagnosis of endometrial lesions in postmenopausal tamoxifen-treated patients. Acta Obstet Gynecol Scand. 81:2002;975-980.
19. Tetlow R., Richmond I., Killick S., Purdie D.W. Errors in the measurement of endometrial depth using transvaginal sonography in postmenopausal women on tamoxifen random error is reduced using saline instillation sonography . Ultrasound Obstet Gynecol. 15:2000;321-326.
20. Hann L.E., Gretz E.M., Bach A.M., Francis S.M. Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. Am J Roentgenol. 177:2001;337-342.
21. Bertelli G., Valenzano M., Costantini S., Rissone R., Angiolini C., Signorini A., Gustavino C. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol. 78:(3, pt 1):2000;275-277.
22. Barakat R.R., Gilewski T.A., Almadrones L., et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer a prospective study using office endometrial biopsy . J Clin Oncol. 18:2000;3459-3463.
23. Deckardt R., Lueken R.P., Gallinat A., Moller C.P., Busche D., Nugent W., et al. Comparison of transvaginal ultrasound, hysteroscopy, and dilatation and curettage in the diagnosis of abnormal vaginal bleeding and intrauterine pathology in perimenopausal and postmenopausal women. J Am Assoc Gynecol Laparosc. 9:2002;277-282.
24. MacKenzie I.Z., Bibby J.G. Critical assessment of dilatation and curettage in 1029 women. Lancet. 9:(2):1978;566-568.
25. Seoud M. Tamoxifen and endometrial pathologies a prospective study . Gynecol Oncol. 75:1999;15-19.
26. Gerber B., Krause A., Muller H., et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer a prospective long-term study using transvaginal ultrasound . J Clin Oncol. 18:2000;3464-3470.
27. Gail M.H., Costantino J.P., Bryant J., et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 91:1999;1829-1846.